Theranostics in Thyroid Cancer.

Friederike Eilsberger, Andreas Pfestroff

Journal: PET clinics 2021;16(3):375-382

PMID: 34053581

Full Text on Elsevier Science View on PubMed

Abstract

The main targeting structure for theranostics in thyroid cancer is the sodium-iodine symporter (NIS), which has been used in clinical routine for the diagnosis and treatment of thyroid diseases for more than 70 years. Because the different iodine (I) nuclides (I, I, I) have the same kinetics, uniquely congruent theranostics are possible in differentiated thyroid cancer. Besides the NIS, there are further possibilities by using expression of somatostatin receptors or the expression of the prostate-specific membrane antigen, for example, in radioiodine-refractory differentiated thyroid cancer, medullary thyroid cancer, or anaplastic thyroid cancer.

Address: University Hospital Marburg, Department of Nuclear Medicine, Baldingerstrasse, 35043 Marburg, Germany. Electronic address: [email protected].; University Hospital Marburg, Department of Nuclear Medicine, Baldingerstrasse, 35043 Marburg, Germany.

DOI: 10.1016/j.cpet.2021.03.007

Link outs

Free resources

Medical:

https://medlineplus.gov/thyroidcancer.html

Other Literature Sources:

https://scite.ai/reports/34053581

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Iodine Radioisotopes, Male, Precision Medicine, Symporters, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms